The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 225.00
Bid: 220.00
Ask: 230.00
Change: 10.00 (4.65%)
Spread: 10.00 (4.545%)
Open: 215.00
High: 234.00
Low: 225.00
Prev. Close: 215.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Faron files patent application for Traumakine

1 Mar 2016 07:00

RNS Number : 5448Q
Faron Pharmaceuticals Oy
01 March 2016
 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

 

 

Faron files patent application to further strengthen protection for its novel Traumakine®

(FP-1201-lyo) formulation

 

TURKU - FINLAND, 1 March 2016 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the drug discovery and development company is pleased to announce that it has filed a national application for a new formulation patent in Finland with filings to be expanded over the next two years to almost all countries worldwide under the Patent Co-operation Treaty (PCT). The patent further protects Faron's final FP-1201-lyo (lyophilised interferon-beta or Traumakine®) formulation for the intravenous treatment of acute respiratory distress syndrome ("ARDS") and other vascular diseases.

Interferon-beta, especially if freeze-dried, is known to form aggregates or stick to container surfaces, requiring careful control of dosing and in-use stability during administration. Faron has developed a proprietary new product formulation for which tests have shown almost 100 per cent recovery of solubilised interferon-beta for intravenous use. With this patent formulation filing, Faron is seeking to protect this discovery for the next 20 years. Based on patent database searches, no similar formulation has been reported previously.

Dr Markku Jalkanen, CEO of Faron, said: "As of today, our Traumakine treatment is the only known intravenously administered human interferon-beta preparation and it is important that dosing is optimal for patients lacking peripheral circulation, as is the case with ARDS patients. We have carefully tested various ingredients to optimise interferon-beta use in these patients and have now completed all necessary tests for patent purposes. If our claims are approved, we could have a proprietary product for the next two decades, further increasing Traumakine's significant, commercial potential. We already have new use patents for interferon-beta in ischaemic conditions and multi organ failure, and this new formulation patent will reinforce our global patent protection strategy".

The new formulation, which has not previously been made public, is already in use in Faron's pivotal, pan-European INTEREST trial, the recruitment of which the Company expects to be completed in 10-16 months from now. Besides several granted patents and pending filings, Faron has also sought exclusivity for Traumakine through orphan drug designations (ODD) and has been successful in Europe regarding ARDS. The Company has also sought ODD in the USA where the application is ongoing. Faron's Japanese licensing partner Maruishi Pharmaceutical, Co. is also planning to file an orphan application in Japan.

 

For more information contact:

Faron Pharmaceuticals Oy

Katja Wallenlind

Phone +358 (50) 577 4807E-mail: katja.wallenlind@faronpharmaceuticals.com

 

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson and Rebecca Anderson

Phone: +44 207 148 7900

 

Whitman Howard Limited, Nominated Broker

Niall Devins, Francis North

Phone: +44 207 659 1234

 

Hume Brophy, PR

Mary Clark, Eva Haas, Hollie Vile

Phone: +44 207 862 6390

E-mail: faron@humebrophy.com

 

About Faron Pharmaceuticals Ltd

Faron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. Faron is based in Turku, Finland. The Company has identified several molecular mechanisms involved in the control of endothelial functions as a source of innovations. Faron currently has a pipeline of products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat acute respiratory distress syndrome ("ARDS"), a rare, severe, life threatening medical condition for which there is currently no approved pharmaceutical treatment. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets including a pre-clinical anti-Clever-1 antibody named Clevegen. Clevegen is focused on converting the immune environment around a tumour from being immune suppressive to immune stimulating representing a novel immuno-oncology approach.

Further information is available at www.faronpharmaceuticals.com.

About Traumakine®

Faron completed a Phase I/II trial in respect of Traumakine® in 2011 where treatment with Traumakine® was associated with an 81% reduction in the odds of 28 day mortality in patients with ARDS. These data were published in The Lancet Respiratory Medicine, a leading medical journal (Bellingan et al. 2014).

The scientific rationale for Traumakine® treatment is based on the proprietary use of room temperature stable formulation of interferon-beta-1a (FP-1201-lyo) for the restoration of the endothelial barrier function in ARDS patients. In Phase I/II trials interferon-beta was found to be safe and well tolerated in ARDS patients and the optimal tolerated dose was established. The selected pharmacodynamic marker for interferon-beta bioactivity showed clear dose response and the treatment target molecule CD73 levels were induced during the dosing period.

The Traumakine® research consortium (www.traumakine.eu) led by Faron has received €6 million funding from the European Union Seventh Framework Programme (FP7) targeting European marketing application as a final milestone of the programme.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUKARRNBAUUUR
Date   Source Headline
28th Jun 20221:47 pmRNSRegistration of New Shares
28th Jun 20227:00 amRNSAnnouncement of Placing
16th Jun 202212:00 pmRNSFaron notice of EGM
15th Jun 20227:00 amRNSFaron Announces Top-Line 12-Month Survival Results
8th Jun 20227:00 amRNSFirst Patient Dosed in Ph I/II BEXMAB Combo Study
1st Jun 20227:00 amRNSExercise of options
30th May 20227:00 amRNSPresentation of Biomarker Analysis at ASCO
16th May 20227:00 amRNSFDA and FIMEA approve BEXMAB study to begin
12th May 20223:50 pmRNSEx Vivo Data Presented at EHA2022 Congress
9th May 20227:00 amRNSMol Cancer Ther Publishes Bexmarilimab Research
4th May 202211:15 amRNSGrant of options
22nd Apr 20221:01 pmRNSBoard Changes
22nd Apr 20221:00 pmRNSResults of AGM
21st Apr 20224:30 pmRNSFaron Presents Melanoma Data at EADO
8th Apr 20223:45 pmRNSManagers’ Transactions
5th Apr 20227:00 amRNSFaron Closes HIBISCUS Trial
25th Mar 20229:00 amRNSNotice of Faron Pharmaceuticals Ltd’s AGM
25th Mar 20227:15 amRNSFaron´s Annual Report 2021 Published
25th Mar 20227:00 amRNSFinancial Statement January 1 to December 31 2021
14th Mar 20227:00 amRNSFaron Publishes Research From INTEREST Trial
9th Mar 20227:00 amRNSPresentation of Biomarker Data at AACR 2022
7th Mar 20227:00 amRNSNotice of 2021 Full-Year Results and Annual Report
4th Mar 20227:00 amRNSFaron presents at upcoming conferences
28th Feb 20225:45 pmRNSFaron Board Issues Warrants to IPF Partners
28th Feb 20227:00 amRNSFaron Obtains Debt Funding from IPF Partners
23rd Feb 20227:00 amRNSFaron Updates on Bexmarilimab Development Program
14th Feb 20227:00 amRNSFaron Announces R&D Day
3rd Feb 202210:40 amRNSScientific Reports Publishes INFORAAA Results
31st Jan 20221:30 pmRNSHoldings in Company
31st Jan 20227:00 amRNSJuho Jalkanen Appointed Chief Operating Officer
28th Jan 20227:00 amRNSGrant of options
24th Jan 20227:00 amRNSFaron at Proactive One2One Investor Forum
17th Jan 20227:00 amRNSFaron to Present at Redeye Fight Cancer Seminar
5th Jan 20227:00 amRNSFaron to Present at H.C. Wainwright BioConnect
4th Jan 20227:00 amRNSFaron Appoints Marie-Louise Fjällskog as CMO
21st Dec 20217:00 amRNSFaron’s financial calendar for 2022
9th Dec 20217:00 amRNSFaron Announces Topline MATINS Biomarker Analysis
1st Dec 20217:00 amRNSChange in Faron’s Management Team
16th Nov 20217:00 amRNSFaron to Present at Jefferies Conference 2021
9th Nov 20217:00 amRNSFaron awarded EUR 3.8 Million in Arbitration Case
3rd Nov 20213:55 pmRNSCellular and Molecular Life Sciences Publication
7th Oct 20217:00 amRNSExercise of options
5th Oct 202111:30 amRNSHolding(s) in Company
1st Oct 20212:00 pmRNSRegistration of Placing Shares with Trade Register
1st Oct 20217:00 amRNSResults of Placing and Issue Price
30th Sep 20214:31 pmRNSProposed Issue and Placing of Shares
17th Sep 20217:00 amRNSPresentation of Updated MATINS Data at ESMO
9th Sep 20217:00 amRNSFaron Announces Presentation at ESMO Congress
7th Sep 20217:00 amRNSFaron to Present at H.C. Wainwright Conference
26th Aug 20217:00 amRNSHalf-Year Financials, January 1 – June 30 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.